Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04134247 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT04134247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04134247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
November 1, 2019
Completion date
November 1, 2021
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory non-hodgkin's lymphoma